{"prompt": "['Cara Therapeutics, Inc., CR845', 'IND 123140, SN 0072', 'Cara Therapeutics, Inc.', 'Confidential', 'Page 8 of 92', 'CR845-CLIN3103', 'The Double-blind Phase of the study will consist of a Screening Visit, a', '7-day Run-in Period and a 12-week Double-blind Treatment Period.', 'Informed consent will be obtained prior to performing any study-', 'specific procedures. The Screening Visit will occur within 7 to 28 days', 'prior to randomization to assess eligibility. The site has the option to', 'conduct the Screening Visit within the Run-in Period at the discretion', 'of the Investigator.', 'Eligible patients will complete a 7-day Run-in Period during the week', 'prior to randomization to confirm eligibility, preferably starting on the', 'first dialysis session of that week (ie, Monday for patients on a', 'Monday-Wednesday-Friday dialysis schedule or Tuesday for patients', 'on a Tuesday-Thursday-Saturday dialysis schedule). The purpose of', 'the Run-in Period is to confirm that each patient has', 'moderate-to-severe pruritus (ie, weekly average worst itch score 5), as', 'measured by the patient-daily reported 24-hour Worst Itching Intensity', 'NRS, and to establish a baseline itch intensity. Patients must not be', 'informed that they need to report a weekly average worst itch score >5', 'to be enrolled in the study. During the first visit of the Run-in Period,', 'patients will be trained on completion of the 24-hour Worst Itching', 'Intensity NRS and will start the reporting of their Worst Itching', 'Intensity NRS daily score. For consistency, patients will be requested', 'to complete the NRS worksheets (either at home or in the dialysis unit,', 'as required) each day at a similar time of day around the normal start', 'time of their dialysis.', 'Patients will be trained on other itch-related patient-reported outcome', '(PRO) worksheets during the Run-in Period or on Day 1 of the', 'Double-blind Treatment Period.', 'If patients continue to meet all inclusion and no exclusion criteria at the', 'end of the 7-day Run-in Period, they will be randomized into the', 'Double-blind Treatment Period in a 1:1 ratio to receive either IV', 'CR845 0.5 mcg/kg or placebo. Patients will be stratified according to', 'their use or non-use of concomitant medications to treat their itch', 'during the week prior to randomization (Run-in Period) as well as the', 'presence or absence of specific medical conditions. These specific', 'medical conditions include:', 'History of fall or fracture (related to fall)', 'Confusional state or mental status change or altered mental', 'status or disorientation', 'Gait disturbance or movement disorder', 'Day 1 of the Double-blind Treatment Period will be defined as the day', 'of administration of the first dose of study drug and will occur', 'preferably on the first dialysis session of the first treatment week (ie,', 'Monday for patients on a Monday-Wednesday-Friday dialysis', 'schedule, or Tuesday for patients on a Tuesday-Thursday-Saturday', 'dialysis schedule). Patients will be administered CR845 or matched', 'placebo as an IV bolus after the end of each dialysis session during the', '10 September 2019', 'Version 2.2']['Cara Therapeutics, Inc., CR845', 'IND 123140, SN 0072', 'Cara Therapeutics, Inc.', 'Confidential', 'Page 9 of 92', 'CR845-CLIN3103', '12-week Double-blind Treatment Period. Each patient is to receive', 'CR845 or placebo 3 times weekly for a total of up to 36 doses.', 'During the Double-blind Treatment Period, patients will continue to', 'report their daily Worst Itching Intensity NRS score over the previous', '24 hours. In addition, during selected study visits (Day 1 and first day', 'of Weeks 5, 9, 11, and 13 [ie, Days 29, 57, 71, and 85]), they will', 'complete other PRO measures (such as Skindex-10 Scale, 5-D Itch', 'Scale, and Patient Global Impression of Change). Patients will be', 'instructed to record patient-reported outcome measurements, including', 'Worst Itching Intensity NRS scores, at a similar time of day, whether', 'in the dialysis unit (on dialysis days) or at home (on non-dialysis days).', 'Blood samples for clinical laboratory tests will be collected at the', 'Screening Visit and on Days 1 and 85. Blood samples for biomarkers', 'will be collected on Days 1 and 85. Electrocardiograms (ECGs) will', 'be monitored at the Screening Visit and on Day 85. Vital signs will be', 'monitored periodically, and adverse events and concomitant', 'medications will be continuously recorded during the Double-blind', 'Phase. Use of antipruritic medications and missed dialysis will be', 'recorded throughout the Double-blind Phase.', 'A Structured Safety Evaluation will be performed once during the', 'Run-in Period and weekly (preferably on Wednesday/Thursday) during', 'the Double-blind Treatment Period. The Structured Safety Evaluation', 'is performed by study staff using a list of specific signs/symptoms (eg,', 'mental status change, falls, gait disturbance).', 'Open-label Extension Phase', 'Patients who received at least 30 doses of study drug (either active or', 'placebo) during the 12-week Double-blind Treatment Period and', 'continue to meet other eligibility criteria will be eligible to receive', 'open-label CR845 for an additional 52 weeks.', 'Each patient will receive CR845 at a dose of 0.5 mcg/kg after each', 'dialysis session, 3 times per week for up to 52 weeks, regardless of', 'whether they had been previously administered placebo or CR845.', 'Prescription dry body weight will be recorded at the start of and every', '12 weeks during the Open-label Extension Phase; if there is a 10% or', 'more change from the prescription dry body weight recorded at', 'Screening, then the CR845 dose will be adjusted according to the', 'newly recorded dry body weight.', 'The first visit and first dosing for the Open-label Extension Phase of', 'the study will occur immediately on the day of the last visit of the', 'Double-blind Treatment Period or up to 1 week following the Double-', 'blind Treatment Period.', 'Patients will complete the 5-D Itch Scale during Weeks 4, 8, 12, 24,', '36, and 52 (preferably at the end of the specified weeks).', 'Clinical laboratory tests, vital signs, adverse events, and concomitant', 'medications will be monitored throughout the Open-label Treatment', 'Period. Blood samples for inflammatory biomarkers will be collected', '10 September 2019', 'Version 2.2']\n\n###\n\n", "completion": "END"}